The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies such as Barzolvolimab (CDX-0159) (Celldex Therapeutics), Rilzabrutinib (Sanofi), Briquilimab…
News provided by PR Newswire.
